Rockville, MD — August 18, 2025 — Leads & Copy — OncoC4, Inc., a biopharmaceutical company focused on developing cancer medicines, has appointed Shiniu Wei as Chief Financial Officer (CFO). Wei brings nearly 20 years of financial strategy and business development experience to the role.
Yang Liu, PhD, Co-Founder, CEO, and CSO of OncoC4, expressed enthusiasm for Wei’s appointment, highlighting his capital markets expertise. Wei previously served as CFO and VP of Investor Relations at GenScript Biotech (HK 1548), where he oversaw financial strategy and fundraising initiatives, including the NASDAQ listing of Legend Biotech.
Wei expressed excitement about joining OncoC4, citing the company’s progress in immune checkpoint therapy and its partnerships, including one with BioNTech. OncoC4 is a biopharmaceutical company engaged in developing novel biologicals for treating cancer and immunological diseases. Its pipeline includes AI-081, a bispecific antibody candidate targeting PD-1 and VEGF, and gotistobart (BNT316/ONC-392), an anti-CTLA-4 antibody candidate being co-developed with BioNTech.
Investor Contact: Alexandra Folias, LifeSci Advisors, afolias@lifesciadvisors.com; Media Contact: Jason Braco, Ph.D., LifeSci Communications, jbraco@lifescicomms.com
Source: OncoC4
